In the phase III STEP 6 trial conducted in Japan and South Korea, semaglutide 2.4 mg resulted in a mean percentage change in body weight from baseline to week 68 of -13.2% (standard error [SE] 0.5), compared with -2.1% (SE 0.8) achieved with placebo, corresponding to a between-group difference of -11.1% (95% confidence interval [CI], -12.9 to -9.2) using the treatment policy estimand
As a neurohormone, oxytocin exerts potent regulatory effects on social behavior, cognition, affiliation, and reward [33, 34]
Centers for Diseases Control and Prevention
There is a significant unmet need for improved therapies that can produce robust and sustained metabolic benefits for patients
0.5 mL Cada 0.5 mL de MOUNJARO 5.0 mg/ 0.5 mL contiene: Tirzepatida 5.0 mg Excipientes: Cloruro de sodio 4.09 mg Fosfato sdico dibsico heptahidrato 0.67 mg cido clorhdrico (solucin) c.s